002675 东诚药业
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.4313.9724.4046.720--
总资产报酬率 ROA (%)2.1912.1992.5803.882--
投入资产回报率 ROIC (%)2.8242.7443.1704.764--

边际利润分析
销售毛利率 (%)50.96647.14044.86742.94240.955
营业利润率 (%)7.7577.69610.43012.5119.124
息税前利润/营业总收入 (%)13.07710.32911.25212.60810.585
净利润/营业总收入 (%)5.6344.9307.7619.8476.668

收益指标分析
经营活动净收益/利润总额(%)103.752100.357133.174123.056157.970
价值变动净收益/利润总额(%)-7.508-5.895-8.340-8.800-3.413
营业外收支净额/利润总额(%)-0.566-0.777-1.299-0.600-0.234

偿债能力分析
流动比率 (X)1.6411.4641.2691.334--
速动比率 (X)1.3161.0950.8060.884--
资产负债率 (%)40.76537.79233.24235.400--
带息债务/全部投入资本 (%)12.26316.55420.06324.577--
股东权益/带息债务 (%)503.857397.083361.642290.453--
股东权益/负债合计 (%)115.691137.302177.740164.050--
利息保障倍数 (X)2.4383.83711.77873.4347.141

营运能力分析
应收账款周转天数 (天)123.217105.54989.56286.3180.000
存货周转天数 (天)157.867183.983197.538178.7860.000